Page 122 - Cellular Imaging in Regenerative Medicine, Cancer and Osteoarthritis

Chapter 5
References
1. Jensen RT, Battey JF, Spindel ER, Benya RV (2008) International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev 60:1-42.
2. Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M (2002) Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14). Clin Cancer Res 8:1139-1146.
3. Sancho V, Di Florio A, Moody TW, Jensen RT (2011) Bombesin receptor-mediated imaging and cytotoxicity: review and current status. Curr Drug Deliv 8:79-134.
4. Moreno P, Ramos-Alvarez I, Moody TW, Jensen RT (2016) Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment. Expert Opin Ther Targets 20:1055-1073.
5. Chatalic KL, Konijnenberg M, Nonnekens J, et al (2016) In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies. Theranostics 6:104-117.
6. Dumont RA, Tamma M, Braun F, et al (2013) Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin. J Nucl Med 54:762-769.
7. Nock BA, Kaloudi A, Lymperis E, et al (2017) Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results. J Nucl Med 58:75-80.
8. Stoykow C, Erbes T, Maecke HR, et al (2016) Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET. Theranostics 6:1641-1650.
9. Bodei L, Ferrari M, Nunn A, et al (2007) 177Lu-AMBA bombesin analogue in hormone refractory prostate cancer patients: a phase I escalation study with single-cycle administrations [abstract]. Eur J Nucl Med Mol Imaging 34 (Supplement 2):S221.
10. Cescato R, Maina T, Nock B, et al (2008) Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 49:318-326.
11. Maina T, Bergsma H, Kulkarni HR, et al (2016) Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [(6)(8)Ga]SB3 and PET/CT. Eur J Nucl Med Mol Imaging 43:964-973.
12. Bakker I, Fröberg AC, Busstra MB, et al (2016) PET imaging of prostate cancer using the GRPr- targeting ligand Sarabesin 3 prior to radical prostatectomy [abstract]. Eur J Nucl Med Mol Imaging 43 (Supplement 1):S1-S734.
13. Povoski SP, Neff RL, Mojzisik CM, et al (2009) A comprehensive overview of radioguided surgery using gamma detection probe technology. World J Surg Oncol 7:11.
14. Bluemel C, Herrmann K, Giammarile F, et al (2015) EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma. Eur J Nucl Med Mol Imaging 42:1750-1766.
15. Giammarile F, Bozkurt MF, Cibula D, et al (2014) The EANM clinical and technical guidelines for lymphoscintigraphy and sentinel node localization in gynaecological cancers. Eur J Nucl Med Mol Imaging 41:1463-1477.
16. Valdes Olmos RA, Vidal-Sicart S, Manca G, et al (2017) Advances in radioguided surgery in oncology. Q J Nucl Med Mol Imaging 61:247-270.
17. Desiato V, Melis M, Amato B, et al (2016) Minimally invasive radioguided parathyroid surgery: A literature review. Int J Surg 28 (Supplement 1):S84-93.
18. Chan BK, Wiseberg-Firtell JA, Jois RH, Jensen K, Audisio RA (2015) Localization techniques for guided surgical excision of non-palpable breast lesions. Cochrane Database Syst Rev 12:CD009206.
19. Cuccurullo V, Di Stasio GD, Mansi L (2017) Radioguided surgery with radiolabeled somatostatin analogs: not only in GEP-NETs. Nucl Med Rev Cent East Eur 20:49-56.
20. Adams S, Baum RP (2000) Intraoperative use of gamma-detecting probes to localize neuroendocrine tumors. Q J Nucl Med 44:59-67.
120